Profile data is unavailable for this security.
About the company
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd is a China-based company primarily engaged in the research, development, production and sales of pharmaceuticals. The Company's products cover therapeutic areas such as anti-tumor, cold and cough, cardiovascular and cerebrovascular, rheumatic and bone pain, antifungal, tonic and tranquilizing, and gynecological. The Company’s main products include sodium cantharidinate and vitamin B6 injection, sodium cantharidinate injection, loquat cough granules, strong loquat dew, loquat cough capsules, Jinwu Gutong capsules, Shanhu Xuanjing, Jingwu capsules, Quantianma capsules, and Yindan Xintai dripping pills. The Company distributes its products within the domestic market and to overseas markets.
- Revenue in CNY (TTM)1.88bn
- Net income in CNY62.34m
- Incorporated1992
- Employees1.27k
- LocationShanghai Shenqi Pharmaceutical Investment Management Co LtdRoom 613Changfa Tower, No. 128, Weihai RoadSHANGHAI 200003ChinaCHN
- Phone+86 2 153750009
- Fax+86 2 153750010
- Websitehttp://www.gzsq.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ginwa Enterprise Group Inc | 550.44m | 78.32m | 2.98bn | 588.00 | 37.04 | 1.88 | -- | 5.42 | 0.2157 | 0.2157 | 1.54 | 4.24 | 0.2885 | 4.56 | 4.97 | 936,120.60 | 4.04 | 0.839 | 4.86 | 0.9762 | 76.30 | 75.14 | 14.00 | 2.83 | 1.84 | -- | 0.0561 | 52.12 | 3.55 | -4.95 | 273.96 | 23.56 | 28.32 | 0.00 |
| Novoprotein Scientific Inc | 147.33m | -65.02m | 3.13bn | 566.00 | -- | 1.49 | -- | 21.22 | -0.9301 | -0.9301 | 2.10 | 29.82 | 0.0664 | 0.7531 | 2.20 | 260,302.10 | -2.93 | 4.36 | -3.02 | 4.58 | 62.01 | 74.11 | -44.13 | 26.35 | 24.75 | -- | 0.0227 | 24.96 | -16.73 | 28.80 | -523.69 | -- | 166.98 | -- |
| GuiZhou YiBai Pharmaceutical Co., Ltd. | 1.91bn | -234.63m | 3.25bn | 5.26k | -- | 1.35 | -- | 1.71 | -0.3003 | -0.3003 | 2.42 | 3.03 | 0.4764 | 1.43 | 9.21 | 362,458.80 | -6.27 | -0.973 | -8.33 | -1.31 | 58.70 | 72.00 | -13.17 | -1.65 | 1.25 | -10.11 | 0.2733 | -- | -22.92 | -8.34 | -406.79 | -- | -13.70 | -- |
| Shanghai Shenqi Pharmactcl Inv Mgt CoLtd | 1.88bn | 62.34m | 3.31bn | 1.27k | 54.79 | 1.49 | -- | 1.76 | 0.1186 | 0.1186 | 3.58 | 4.37 | 0.5981 | 4.66 | 5.41 | 1,487,675.00 | 1.85 | -0.6947 | 2.33 | -0.8656 | 44.60 | 53.83 | 3.10 | -1.04 | 2.57 | 31.84 | 0.0745 | -- | -12.48 | 1.23 | 25.24 | -3.20 | -13.91 | -- |
| Lionco Pharmaceutical Group Co Ltd | 430.61m | -118.38m | 3.41bn | 436.00 | -- | 4.64 | -- | 7.92 | -0.1609 | -0.1609 | 0.5928 | 1.02 | 0.3578 | 3.93 | 2.41 | 987,638.40 | -9.84 | -2.45 | -11.09 | -3.13 | 45.89 | 72.39 | -27.49 | -9.67 | 2.80 | -2.73 | 0.2791 | -- | 92.95 | -25.32 | 13.68 | -- | -4.03 | -- |
| Shanghai Hile Bio-Technology Co Ltd | 246.35m | 171.34m | 3.54bn | 366.00 | 18.11 | 2.32 | -- | 14.37 | 0.2998 | 0.2998 | 0.3895 | 2.34 | 0.1438 | 0.8346 | 2.49 | 673,097.90 | 11.90 | 4.15 | 14.28 | 5.65 | 75.26 | 52.88 | 82.75 | 25.09 | 6.92 | -- | 0.0106 | 26.17 | 12.59 | -0.5053 | 172.28 | 69.73 | -26.47 | 67.20 |
Data as of Feb 10 2026. Currency figures normalised to Shanghai Shenqi Pharmaceutical Investment Management Co Ltd's reporting currency: Chinese Yuan Renminbi CNY
0.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Gfund Management Co., Ltd.as of 30 Jun 2025 | 1.18m | 0.25% |
| Broad Fund Management Co. Ltd.as of 30 Jun 2025 | 915.90k | 0.19% |
| Goldstate Capital Fund Management Co., Ltd.as of 30 Jun 2025 | 500.00k | 0.10% |
| Shanghai Guotai Junan Securities Assets Management Co., Ltd.as of 30 Jun 2025 | 158.40k | 0.03% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025 | 131.70k | 0.03% |
| Wanjia Asset Management Co., Ltd.as of 30 Jun 2025 | 42.40k | 0.01% |
| Hongde Fund Management Co., Ltd.as of 30 Jun 2025 | 41.00k | 0.01% |
| Truvalue Asset Management Co. Ltd.as of 30 Jun 2025 | 35.00k | 0.01% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2025 | 22.70k | 0.01% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 19.50k | 0.00% |
More ▼
Data from 30 Jun 2025 - 30 Nov 2025Source: FactSet Research Systems Inc.
